|
Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer. |
|
|
Consulting or Advisory Role - Oncolinea Pharmaceuticals |
Research Funding - Bayer (Inst); Janssen Scientific Affairs (Inst); Lantheus Medical Imaging (Inst); Progenics (Inst) |
Patents, Royalties, Other Intellectual Property - I am listed as inventor on patents related to PyIm polyamides that have been licensed by Gene Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Janssen (Inst); Lantheus Medical Imaging (Inst) |
Travel, Accommodations, Expenses - Varian Medical Systems |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Galera Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Viewray |
Research Funding - ViewRay |
|
|
Stock and Other Ownership Interests - ImaginAb |
Consulting or Advisory Role - Astellas Pharma |
Speakers' Bureau - Bayer Schering Pharma; Genomic Health; ImaginAb; Janssen Oncology; Pfizer |
Patents, Royalties, Other Intellectual Property - patents surrounding discovery of PSCA and N-cadherin, owned by UCLA (Inst) |
|
|
Stock and Other Ownership Interests - ViewRay |
Honoraria - Boston Scientific; Janssen Oncology; Varian Medical Systems; ViewRay; ViewRay |
Consulting or Advisory Role - Boston Scientific; Janssen |
Research Funding - Janssen Oncology (Inst); Point Biopharma (Inst); ViewRay; ViewRay |
|
|
Consulting or Advisory Role - Canon Medical System |
Research Funding - GE Healthcare (Inst); Lantheus Medical Imaging (Inst); Novartis (Inst); POINT Biopharma (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - Aravalent; Survalent |
Stock and Other Ownership Interests - Oncovalent Therapeutics; Survalent |
Consulting or Advisory Role - Ambrx; Amgen; INMune Bio; Precisca; Roivant |
Speakers' Bureau - Bayer; Johnson & Johnson |
Research Funding - Arvinas (Inst); Fortis (Inst); Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst); Progenics |
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet. |
Travel, Accommodations, Expenses - Johnson & Johnson |